Associated Genetic Biomarkers
Associated Diseases
Associated Pathways

Overview

Location [1]
15q15.1
Pathway
DNA damage/repair
Protein [2]
DNA repair protein RAD51 homolog 1
Synonyms [1]
BRCC5, HsT16930, HsRad51, FANCR, RAD51A, HRAD51, MRMV2, RECA

RAD51 recombinase (RAD51) is a gene that encodes a protein that functions in homologous recombination and DNA repair. Missense mutations, nonsense mutations, silent mutations, and frameshift insertions are observed in cancers such as endometrial cancer, intestinal cancer, and cancers of the urinary tract.

RAD51 is altered in 0.38% of all cancers with breast invasive ductal carcinoma, lung adenocarcinoma, colon adenocarcinoma, cutaneous melanoma, and bladder urothelial carcinoma having the greatest prevalence of alterations [3].

RAD51 GENIE Cases - Top Diseases

The most common alterations in RAD51 are RAD51 Mutation (0.20%), RAD51 Loss (0.10%), RAD51 Amplification (0.03%), RAD51 A224G (0.01%), and RAD51 Nonsense (0.01%) [3].

RAD51 GENIE Cases - Top Alterations

Significance of RAD51 in Diseases

Malignant Solid Tumor +

Breast Carcinoma +

Prostate Adenocarcinoma +

Ovarian Carcinoma +

Prostate Carcinoma +

Primary Peritoneal Carcinoma +

Fallopian Tube Carcinoma +

Urothelial Carcinoma +

Adenocarcinoma Of The Gastroesophageal Junction +

Pancreatic Adenocarcinoma +

Endometrial Carcinoma +

Non-Small Cell Lung Carcinoma +

Cervical Carcinoma +

Clear Cell Renal Cell Carcinoma +

Gastric Adenocarcinoma +

Non-Hodgkin Lymphoma +

Small Cell Lung Carcinoma +

Bladder Urothelial Carcinoma +

Soft Tissue Sarcoma +

Melanoma +

Colorectal Carcinoma +

Cholangiocarcinoma +

Esophageal Adenocarcinoma +

Gastric Carcinoma +

Gastrointestinal Stromal Tumor +

Head And Neck Squamous Cell Carcinoma +

High Grade Ovarian Serous Adenocarcinoma +

Osteosarcoma +

Pancreatic Carcinoma +

Squamous Cell Lung Carcinoma +

Bladder Carcinoma +

Colorectal Adenocarcinoma +

Malignant Intestinal Neoplasm +

Ampulla Of Vater Carcinoma +

Anal Carcinoma +

B-Cell Non-Hodgkin Lymphoma +

Bile Duct Adenocarcinoma +

Biliary Tract Carcinoma +

Diffuse Large B-Cell Lymphoma +

Esophageal Carcinoma +

Ewing Sarcoma +

Head And Neck Carcinoma +

Hepatocellular Carcinoma +

Histiocytic And Dendritic Cell Neoplasm +

Kidney Carcinoma +

Leiomyosarcoma +

Low Grade Ovarian Serous Adenocarcinoma +

Malignant Esophagogastric Neoplasm +

Malignant Gastric Neoplasm +

Malignant Mesothelioma +

Malignant Ovarian Epithelial Tumor +

Malignant Small Intestinal Neoplasm +

Mantle Cell Lymphoma +

Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma +

Mesothelioma +

Multiple Myeloma +

Neuroblastoma +

Ovarian Clear Cell Adenocarcinoma +

Pancreatic Ductal Adenocarcinoma +

Penile Carcinoma +

Rhabdomyosarcoma +

Uveal Melanoma +

Vaginal Carcinoma +

Vulvar Carcinoma +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.